Therapeutic targeting of AKT has advanced through three inhibitor classes: PH domain competitors (perifosine), allosteric inhibitors (MK-2206), and ATP-competitive agents (GSK2110183, GSK2141795, GDC-0068, and AZD5363), which demonstrated significant anti-tumor efficacy in multiple cancer types across phase I-III clinical trials (22). This evidence concerns the gene AKT1 and neoplasm.